These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 21983031)

  • 41. Targeting RNA binding proteins involved in neurodegeneration.
    Romano M; Buratti E
    J Biomol Screen; 2013 Oct; 18(9):967-83. PubMed ID: 23954928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.
    Zhao J; Du Y; Horton JR; Upadhyay AK; Lou B; Bai Y; Zhang X; Du L; Li M; Wang B; Zhang L; Barbieri JT; Khuri FR; Cheng X; Fu H
    Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16212-6. PubMed ID: 21908710
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Hedgehog signaling pathway--implications for drug targets in cancer and neurodegenerative disorders.
    Bak M; Hansen C; Tommerup N; Larsen LA
    Pharmacogenomics; 2003 Jul; 4(4):411-29. PubMed ID: 12831321
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical modulators working at pharmacological interface of target proteins.
    Jeon YH; Lee JY; Kim S
    Bioorg Med Chem; 2012 Mar; 20(6):1893-901. PubMed ID: 22227462
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Downregulation of 14-3-3 Proteins in a Kainic Acid-Induced Neurotoxicity Model.
    Smani D; Sarkar S; Raymick J; Kanungo J; Paule MG; Gu Q
    Mol Neurobiol; 2018 Jan; 55(1):122-129. PubMed ID: 28840498
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of the 14-3-3 protein family in health, disease, and drug development.
    Aghazadeh Y; Papadopoulos V
    Drug Discov Today; 2016 Feb; 21(2):278-87. PubMed ID: 26456530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cytoplasmic stress granules: Dynamic modulators of cell signaling and disease.
    Mahboubi H; Stochaj U
    Biochim Biophys Acta Mol Basis Dis; 2017 Apr; 1863(4):884-895. PubMed ID: 28095315
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sigma1 Pharmacology in the Context of Cancer.
    Kim FJ; Maher CM
    Handb Exp Pharmacol; 2017; 244():237-308. PubMed ID: 28744586
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
    Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
    Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases.
    Cores Á; Piquero M; Villacampa M; León R; Menéndez JC
    Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32545924
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A; Blagg BS
    Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Highlight: Perspectives of molecular neuroscience in health and disease.
    Heumann R
    Biol Chem; 2016 Mar; 397(3):175. PubMed ID: 26812788
    [No Abstract]   [Full Text] [Related]  

  • 53. The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention.
    Huang Y; Todd N; Thathiah A
    Curr Opin Pharmacol; 2017 Feb; 32():96-110. PubMed ID: 28288370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative splicing as a biomarker and potential target for drug discovery.
    Le KQ; Prabhakar BS; Hong WJ; Li LC
    Acta Pharmacol Sin; 2015 Oct; 36(10):1212-8. PubMed ID: 26073330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Natural products as modulator of autophagy with potential clinical prospects.
    Wang P; Zhu L; Sun D; Gan F; Gao S; Yin Y; Chen L
    Apoptosis; 2017 Mar; 22(3):325-356. PubMed ID: 27988811
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Deubiquitylating enzymes and drug discovery: emerging opportunities.
    Harrigan JA; Jacq X; Martin NM; Jackson SP
    Nat Rev Drug Discov; 2018 Jan; 17(1):57-78. PubMed ID: 28959952
    [TBL] [Abstract][Full Text] [Related]  

  • 57. NF-kappa B as a therapeutic target in neurodegenerative diseases.
    Camandola S; Mattson MP
    Expert Opin Ther Targets; 2007 Feb; 11(2):123-32. PubMed ID: 17227229
    [TBL] [Abstract][Full Text] [Related]  

  • 58. J-domain proteins interaction with neurodegenerative disease-related proteins.
    Ayala Mariscal SM; Kirstein J
    Exp Cell Res; 2021 Feb; 399(2):112491. PubMed ID: 33460589
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Profiling withanolide A for therapeutic targets in neurodegenerative diseases.
    Crane EA; Heydenreuter W; Beck KR; Strajhar P; Vomacka J; Smiesko M; Mons E; Barth L; Neuburger M; Vedani A; Odermatt A; Sieber SA; Gademann K
    Bioorg Med Chem; 2019 Jun; 27(12):2508-2520. PubMed ID: 30929949
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
    Cox AD; Der CJ; Philips MR
    Clin Cancer Res; 2015 Apr; 21(8):1819-27. PubMed ID: 25878363
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.